33469-11-3

Basic information

• Product Name: Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]-
• Synonyms: Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]-;4-[5-(Trifluoromethyl)-1H-imidazol-2-yl]-benzonitrile
• CAS NO: 33469-11-3
• Molecular Formula: C₁₁H₆F₃N₃
• Molecular Weight: 237.1806496
• Mol File: 33469-11-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 412.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 9.34±0.10(Predicted)
• CAS DataBase Reference: Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]-(33469-11-3)
• EPA Substance Registry System: Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]-(33469-11-3)

Safety Data

• Hazardous Substances Data: 33469-11-3(Hazardous Substances Data)

Usage

General Description

Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]- is a chemical compound with the molecular formula C11H7F3N4. It is a derivative of benzonitrile and contains a trifluoromethyl group and an imidazole ring. Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]- is often used in research and pharmaceutical development due to its potential biological activity and its ability to interact with biological systems. It may be used as a building block in the synthesis of various pharmaceutical compounds and may also have potential applications in the development of new drugs. Additionally, it may have uses in other fields such as material science and organic chemistry.

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Relevant articles and documents

SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.